Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial
Aflibercept 8 mg has similar efficacy and safety to aflibercept 2 mg when administered at extended dosing intervals in both the Japan and non-Japan subgroups, consistent with the overall PULSAR results.
Authors
- Rafia Bhore
- Tetsuju Sekiryu
- Shigeru I. Honda (ORCID: https://orcid.org/0000-0002-0632-997X)
- Genichiro Kishino
- Robert Vitti
- Ursula Schmidt-Ott
- Andrea Schulze
- Alyson J. Berliner
- Kimberly Reed
- Yenchieh Cheng
- Takuto Yamashita
- Xin Zhang (ORCID: https://orcid.org/0000-0001-5008-0879)
- Tsutomu Yasukawa
- Min Zhao
- Hideki Koizumi
- Karen W. Chu
- Sergio Leal
- on behalf of the DIABETIC-IC study investigators
- Tomohiro Iida
- Ikuko Fujita
Institutions
- Fukushima Medical University (JP)
- Regeneron (United States) (US)
- University of the Ryukyus (JP)
- Nagoya City University (JP)
- Bayer (Switzerland) (CH)
- Tokyo Women's Medical University (JP)
- Bayer (China) (CN)
- Hakodate Central General Hospital (JP)
- Aizawa Hospital (JP)
- Bayer (Japan) (JP)
- Osaka Metropolitan University (JP)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Japanese Journal of Ophthalmology
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1007/s10384-025-01270-8
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer
- Regeneron Pharmaceuticals